Allurion Technologies Inc. (ALUR) 10-Year Financial Performance & Capital Metrics

ALUR • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

AboutAllurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.Show more

Revenue $32M -39.9%
EBITDA -$49M +37.2%
Net Income -$26M +67.6%
EPS (Diluted) -11.64 +79.9%
Gross Margin 66.97% -13.7%
EBITDA Margin -153.23% -4.6%
Operating Margin -156.33% -5.7%
Net Margin -81.43% +46.0%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -22.17 -196.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 57.9% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-5.66%

TTM-50.49%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-40%

EPS CAGR

10Y-

5Y-

3Y-

TTM34.67%

ROCE

10Y Avg-445.02%

5Y Avg-445.02%

3Y Avg-625.61%

Latest-496.1%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	47.38M	1.29	2.63	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.26M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.55M	2.62	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	29.01M	3.55	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.85M	1.70	-0.12	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	21.55M	1.76	-0.15	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.23M	2.82	-0.26			-380.42%	0.30
TELATELA Bio, Inc.	44.98M	1.01	-0.76	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	38.24M	64.21M	53.47M	32.11M
Revenue Growth %	-	-	0.68%	-0.17%	-0.4%
Cost of Goods Sold+	0	9.05M	13.48M	11.97M	10.61M
COGS % of Revenue	-	0.24%	0.21%	0.22%	0.33%
Gross Profit+	0	29.19M	50.73M	41.5M	21.5M
Gross Margin %	-	0.76%	0.79%	0.78%	0.67%
Gross Profit Growth %	-	-	0.74%	-0.18%	-0.48%
Operating Expenses+	5.17K	41.69M	82.74M	120.58M	71.7M
OpEx % of Revenue	-	1.09%	1.29%	2.26%	2.23%
Selling, General & Admin	4.56K	35.96M	65.77M	92.88M	54.33M
SG&A % of Revenue	-	0.94%	1.02%	1.74%	1.69%
Research & Development	0	5.73M	16.97M	27.69M	17.37M
R&D % of Revenue	-	0.15%	0.26%	0.52%	0.54%
Other Operating Expenses	610	0	0	0	0
Operating Income+	-5.17K	-12.5M	-32.01M	-79.08M	-50.2M
Operating Margin %	-	-0.33%	-0.5%	-1.48%	-1.56%
Operating Income Growth %	-	-2417.46%	-1.56%	-1.47%	0.37%
EBITDA+	201.13K	-11.79M	-31.11M	-78.33M	-49.2M
EBITDA Margin %	-	-0.31%	-0.48%	-1.47%	-1.53%
EBITDA Growth %	-	-59.64%	-1.64%	-1.52%	0.37%
D&A (Non-Cash Add-back)	206.3K	707K	895K	746K	997K
EBIT	-5.17K	-8.72M	-33.17M	-69.78M	-23.17M
Net Interest Income+	0	-3.67M	-4.43M	-10.57M	-2.26M
Interest Income	0	0	0	0	0
Interest Expense	0	3.67M	4.43M	10.57M	2.26M
Other Income/Expense	0	115K	-5.59M	-1.26M	24.77M
Pretax Income+	-5.17K	-12.39M	-37.6M	-80.34M	-25.43M
Pretax Margin %	-	-0.32%	-0.59%	-1.5%	-0.79%
Income Tax+	0	0	143K	264K	718K
Effective Tax Rate %	1%	1%	1%	1%	1.03%
Net Income+	-5.17K	-12.39M	-37.74M	-80.61M	-26.15M
Net Margin %	-	-0.32%	-0.59%	-1.51%	-0.81%
Net Income Growth %	-	-2395.21%	-2.05%	-1.14%	0.68%
Net Income (Continuing)	-5.17K	-12.39M	-37.74M	-80.61M	-26.15M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	0.00	-0.25	-37.75	-57.83	-11.64
EPS Growth %	-	-	-150%	-0.53%	0.8%
EPS (Basic)	0.00	-0.25	-37.75	-57.83	-11.64
Diluted Shares Outstanding	107.81M	54.45M	1.08M	1.42M	2.25M
Basic Shares Outstanding	107.81M	54.42M	999.74K	1.39M	2.25M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	47.09K	37.33M	43.38M	64.82M	27.16M
Cash & Short-Term Investments	47.09K	25.84M	7.68M	38.04M	15.38M
Cash Only	47.09K	25.84M	7.68M	38.04M	15.38M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	6.83M	29.35M	18.19M	7.13M
Days Sales Outstanding	-	65.21	166.81	124.2	81.09
Inventory	0	2.71M	3.87M	6.17M	3.4M
Days Inventory Outstanding	-	109.48	104.61	188.17	117
Other Current Assets	0	0	2.49M	2.41M	1.24M
Total Non-Current Assets+	282.88K	2.02M	7.99M	6.9M	5.66M
Property, Plant & Equipment	0	1.71M	5.28M	6.39M	4.55M
Fixed Asset Turnover	-	22.31x	12.16x	8.37x	7.06x
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	862.55M	0	384K	0
Other Non-Current Assets	282.88K	-862.24M	2.71M	121K	1.11M
Total Assets+	329.96K	39.35M	51.37M	71.71M	32.81M
Asset Turnover	-	0.97x	1.25x	0.75x	0.98x
Asset Growth %	-	118.26%	0.31%	0.4%	-0.54%
Total Current Liabilities+	310.13K	31.61M	75.87M	65.42M	18.86M
Accounts Payable	0	1.62M	5.81M	10.38M	6.57M
Days Payables Outstanding	-	65.24	157.23	316.49	226.15
Short-Term Debt	170K	24.14M	53.36M	38.64M	0
Deferred Revenue (Current)	0	202K	0	0	0
Other Current Liabilities	140.13K	2.23M	3.45M	13.81M	1.05M
Current Ratio	0.15x	1.18x	0.57x	0.99x	1.44x
Quick Ratio	0.15x	1.09x	0.52x	0.90x	1.26x
Cash Conversion Cycle	-	109.44	114.2	-4.11	-28.06
Total Non-Current Liabilities+	0	42.02M	7.82M	76.77M	91.93M
Long-Term Debt	0	2M	3.1M	0	35.71M
Capital Lease Obligations	0	0	2.16M	2.31M	1.34M
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	40.02M	2.55M	74.47M	54.87M
Total Liabilities	310.13K	73.64M	83.68M	142.2M	110.79M
Total Debt+	170K	26.14M	59.53M	41.86M	37.92M
Net Debt	122.91K	300K	51.85M	3.82M	22.54M
Debt / Equity	8.57x	-	-	-	-
Debt / EBITDA	0.85x	-	-	-	-
Net Debt / EBITDA	0.61x	-	-	-	-
Interest Coverage	-	-3.41x	-7.23x	-7.48x	-22.17x
Total Equity+	19.83K	-34.28M	-32.31M	-70.49M	-77.98M
Equity Growth %	-	-1729.86%	0.06%	-1.18%	-0.11%
Book Value per Share	0.00	-0.63	-30.01	-49.52	-34.70
Total Shareholders' Equity	19.83K	-34.28M	-32.31M	-70.49M	-77.98M
Common Stock	2.16K	51K	3K	5K	3K
Retained Earnings	-5.17K	-94.45M	-132.19M	-212.8M	-222.21M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	-700K	-8.37M
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-35	-14.33M	-46.98M	-63.98M	-42.3M
Operating CF Margin %	-	-0.37%	-0.73%	-1.2%	-1.32%
Operating CF Growth %	-	-409399%	-2.28%	-0.36%	0.34%
Net Income	-5.17K	-12.39M	-37.74M	-80.61M	-26.15M
Depreciation & Amortization	0	707K	2M	746K	997K
Stock-Based Compensation	0	313K	437K	8.36M	3.06M
Deferred Taxes	0	0	1.27M	0	0
Other Non-Cash Items	0	-1.47M	840K	7.33M	-21.8M
Working Capital Changes	5.13K	-1.5M	-13.79M	194K	1.6M
Change in Receivables	0	-927K	-22.82M	-1.32M	8.98M
Change in Inventory	0	-1.28M	-1.15M	-3.71M	543K
Change in Payables	0	-488K	3.32M	4.66M	-3.92M
Cash from Investing+	0	-912K	-1.55M	-1.61M	-611K
Capital Expenditures	0	-912K	-1.55M	-1.61M	-611K
CapEx % of Revenue	-	0.02%	0.02%	0.03%	0.02%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	47.13K	28.95M	30.54M	95.99M	20.21M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	-147.88K	1K	-548K	95.7M	-1.33M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-40	-15.24M	-48.53M	-65.59M	-42.91M
FCF Margin %	-	-0.4%	-0.76%	-1.23%	-1.34%
FCF Growth %	-	-381024%	-2.18%	-0.35%	0.35%
FCF per Share	0.00	-0.28	-45.07	-46.08	-19.10
FCF Conversion (FCF/Net Income)	0.01x	1.16x	1.24x	0.79x	1.62x
Interest Paid	0	1.32M	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-26.07%	-	-	-	-
Return on Invested Capital (ROIC)	-	-	-122.91%	-	-
Gross Margin	-	76.33%	79%	77.61%	66.97%
Net Margin	-	-32.39%	-58.78%	-150.76%	-81.43%
Debt / Equity	8.57x	-	-	-	-
Interest Coverage	-	-3.41x	-7.23x	-7.48x	-22.17x
FCF Conversion	0.01x	1.16x	1.24x	0.79x	1.62x
Revenue Growth	-	-	67.91%	-16.73%	-39.94%

Revenue by Geography

	2024
All Other Countries	24.04M
All Other Countries Growth	-
SPAIN	4.01M
SPAIN Growth	-
FRANCE	2.49M
FRANCE Growth	-

Frequently Asked Questions

Growth & Financials

Allurion Technologies Inc. (ALUR) reported $17.2M in revenue for fiscal year 2024.

Allurion Technologies Inc. (ALUR) saw revenue decline by 39.9% over the past year.

Allurion Technologies Inc. (ALUR) reported a net loss of $43.3M for fiscal year 2024.

Dividend & Returns

Allurion Technologies Inc. (ALUR) had negative free cash flow of $36.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener